New combo therapy aims to boost Cancer-Killing power of CAR-T

NCT ID NCT07098364

Summary

This early-phase study is testing the safety and effectiveness of a new drug called ST-067 when given alongside a personalized immune cell therapy (CAR-T) for patients with aggressive large B-cell lymphoma that has come back or not responded to other treatments. The goal is to see if ST-067 can help the CAR-T cells work better and last longer to control the cancer. The study will enroll about 33 adults to find the best dose and see how well the combination works.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.